Cancer Therapy
Pharmaceutical Sciences
Matthew K. Hadden
Professor/Pharmaceutical Science

Are you Matthew K. Hadden?

How to update your information.
Grants

10 Grants

Identification of Small Molecule Inhibitors of m6A Reader Protein YTHDF2
Sponsor: Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation
Authors: Matthew K Hadden
Funding: $0
2025-01-01 - 2025-12-31
Molecules in the Media
Sponsor: Provost's Office - General Education Oversight Committee
Authors: Kyle Hadden, Marcy J Balunas
Funding: $0
2014-06-01 - 2016-05-31
Inhibition of Translesion Synthesis as a Novel Strategy for Cancer Chemotherapy
Sponsor: DHHS/NIH/National Cancer Institute
Authors: Matthew K Hadden
Funding: $0
2025-06-01 - 2030-05-31
METTL1 inhibitors as chemical probes of RNA methylaton
Sponsor: DHHS/NIH/National Cancer Institute
Authors: Matthew K Hadden
Funding: $0
2025-07-01 - 2028-06-30
Targeting 5-methylcytosine RNA binding protein YBX1 for small molecule anti-cancer therapy
Sponsor: American Foundation for Pharmaceutical Education
Authors: Matthew K Hadden
Funding: $0
2025-06-01 - 2026-08-31
Adaptable Protein Interactions in Translesion Synthesis
Sponsor: NSF/National Science Foundation/University of Connecticut Health Center
Authors: Matthew K Hadden
Funding: $0
2025-01-01 - 2028-12-31
Targeting GLI1 Fusion Proteins in Rare Mesenchymal Neoplasms
Sponsor: DOD/Department of Defense
Authors: Matthew K Hadden
Funding: $0
2025-07-01 - 2028-06-30
Small molecule regulators of YTHDF1 and YTHDF2 function
Sponsor: DHHS/NIH/National Cancer Institute
Authors: Matthew K Hadden
Funding: $0
2025-04-01 - 2027-03-31
Targeting replication stress avoidance in cancer
Sponsor: DHHS/NIH/National Cancer Institute/University of Massachusetts Medical School
Authors: Matthew K Hadden
Funding: $379,643
2020-03-01 - 2025-02-28
Inhibition of Translesion Synthesis as a Novel Strategy for Cancer Chemotherapy
Sponsor: DHHS/NIH/National Cancer Institute
Authors: Matthew K Hadden
Funding: $2,549,587
2019-06-10 - 2025-05-31